EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease

Ping Bai, Yu Lan, Yan Liu, Prasenjit Mondal, Ashley Gomm, Yulong Xu, Yanli Wang, Yongle Wang, Leyi Kang, Lili Pan, Frederick A Bagdasarian, Madelyn Hallisey und 9 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202309021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Ping Bai und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers S…. Hauptthemen laut MEDLINE: Alzheimer Disease, Positron-Emission Tomography, Receptor-Interacting Protein Serine-Threonine Kinases, Brain. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Drug Discovery Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting receptor‐interacting protein kinase 1 (RIPK1) has emerged as a promising therapeutic stratagem for neurodegenerative disorders, particularly Alzheimer's disease (AD). A positron emission tomography (PET) probe enabling brain RIPK1 imaging can provide a powerful tool to unveil the neuropathology associated with RIPK1. Herein, the development of a new PET radioligand, [ 11 C]CNY‐10 is reported, which may enable brain RIPK1 imaging. [ 11 C]CNY‐10 is radiosynthesized with a high radiochemical yield (41.8%) and molar activity (305 GBq/µmol). [ 11 C]CNY‐10 is characterized by PET imaging in rodents and a non‐human primate, demonstrating good brain penetration, binding specificity, and a suitable clearance kinetic profile. It is performed autoradiography of [ 11 C]CNY‐10 in human AD and healthy control postmortem brain tissues, which shows strong radiosignal in AD brains higher than healthy controls. Subsequently, it is conducted further characterization of RIPK1 in AD using [ 11 C]CNY‐10‐based PET studies in combination with immunohistochemistry leveraging the 5xFAD mouse model. It is found that AD mice revealed RIPK1 brain signal significantly higher than WT control mice and that RIPK1 is closely related to amyloid plaques in the brain. The studies enable further translational studies of [ 11 C]CNY‐10 for AD and potentially other RIPK1‐related human studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePositron-Emission TomographyReceptor-Interacting Protein Serine-Threonine KinasesBrainAnimalsMiceHumansDisease Models, AnimalRadiopharmaceuticalsMaleRatsFemaleAutoradiographyCarbon Radioisotopes

Stichwörter der Autor:innen

Alzheimer's diseaseNecroptosisNeuroinflammationPositron emission tomographyRIPK1Radioligand[11C]CNY‐10

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanRadiopharmaceuticalsCarbon Radioisotopes

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicin…
  • Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
  • Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, C…
  • Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA, 02129, USA.

ORCID-Profile: Changning Wang

Förderung

  • NIA NIH HHS
  • Alzheimer's Drug Discovery Foundation

Zitieren

APA

Bai, P., Lan, Y., Liu, Y., Mondal, P., Gomm, A., Xu, Y., Wang, Y., Wang, Y., Kang, L., Pan, L., Bagdasarian, F. A., Hallisey, M., Lobo, F., Varela, B., Choi, S. H., Gomperts, S. N., Wey, H. Y., Shen, S., Tanzi, R. E., …, & Zhang, C. (2024). Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease. Advanced Science. https://doi.org/10.1002/advs.202309021

Vancouver

Bai P, Lan Y, Liu Y, Mondal P, Gomm A, Xu Y, et al. Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease. Advanced Science. 2024. doi:10.1002/advs.202309021

BibTeX
@article{Bai2024,
  author = {Bai, Ping and Lan, Yu and Liu, Yan and Mondal, Prasenjit and Gomm, Ashley and Xu, Yulong and Wang, Yanli and Wang, Yongle and Kang, Leyi and Pan, Lili and Bagdasarian, Frederick A and Hallisey, Madelyn and Lobo, Fleur and Varela, Breanna and Choi, Se Hoon and Gomperts, Stephen N and Wey, Hsiao-Ying and Shen, Shiqian and Tanzi, Rudolph E and Wang, Changning and Zhang, Can},
  title = {Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202309021}
}
Kostenlos starten →